CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy.
• CD30 is a transmembrane protein expressed on various immune cells.
• Targeted therapies are crucial for refractory/relapsed ALL.

Purpose of the Study:

• To evaluate CD30 expression in T-cell and B-cell ALL.
• To assess the potential of anti-CD30-targeted therapy in ALL.

Main Methods:

• Multicolor flow cytometry immunophenotyping of bone marrow specimens.
• Analysis of 78 patients (34 T-ALL, 44 B-ALL), predominantly adults with refractory/relapsed disease.
• Assessment of CD30 expression using a 20% cut-off.

Main Results:

• CD30 expression was detected in 38% of T-ALL and 13% of B-ALL cases.
• CD30 expression significantly increased during high-dose chemotherapy in T-ALL patients (p = 0.025).
• No significant correlation between CD30 expression and Philadelphia chromosome/BCR-ABL1 fusion was observed.

Conclusions:

• CD30 is expressed in a notable subset of T-ALL patients.
• Up-regulation of CD30 during chemotherapy suggests a dynamic expression pattern in T-ALL.
• Anti-CD30 therapy presents a potential treatment strategy for refractory/relapsed T-ALL.